List of insiders holdings for Fulcrum Therapeutics Inc.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Insider Holder Name | Report Date Time | Shares Owned Directly Indirectly | Total Shares Owned | Filing |
| RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP Kolchinsky Peter Shah Rajeev M. 10% Owner | 2024-02-14 17:01:37 | 11,609,704 0 | 11,609,704 | Form 13G |
| LEVIN MARK J Director 10% Owner | 2021-11-12 17:31:37 | 75,800 4,970,625 | 5,046,425 | Form 4 |
| Third Rock Ventures III L.P. Third Rock Ventures GP III L.P. TRV GP III LLC TEPPER ROBERT I 10% Owner | 2024-02-14 16:19:04 | 2,343,154 0 | 2,343,154 | Form 13G |
| Third Rock Ventures IV L.P. Third Rock Ventures GP IV L.P. TRV GP IV LLC 10% Owner | 2020-02-05 16:33:55 | 2,343,154 0 | 2,343,154 | Form 13G |
| Third Rock Ventures III L.P. Third Rock Ventures GP III L.P. TRV GP III LLC STARR KEVIN P TEPPER ROBERT I 10% Owner | 2024-02-14 16:19:04 | 2,343,154 0 | 2,343,154 | Form 13G |
| GLAXOSMITHKLINE PLC 10% Owner | 2021-09-27 06:01:18 | 1,785,714 0 | 1,785,714 | Form 13G |
| Casdin Capital LLC Casdin Partners Master Fund L.P. Casdin Partners GP LLC Casdin Eli 10% Owner | 2021-02-11 10:23:04 | 1,241,176 0 | 1,241,176 | Form 13G |
| 6 Dimensions Capital L.P. 10% Owner | 2019-07-22 16:32:02 | 559,821 0 | 559,821 | Form 4 |
| Sanofi 10% Owner | 2019-07-29 10:13:05 | 558,035 0 | 558,035 | Form 13G |
| Section 32 Fund 2 LP Section 32 GP 2 LLC Maris William J 10% Owner | 2019-07-22 16:30:46 | 464,285 0 | 464,285 | Form 4 |
| Horn Patrick Taylor Chief Medical Officer | 2024-03-20 16:15:10 | 400,000 0 | 400,000 | Form 4 |
| Arroyo Santiago Chief Medical Officer | 2022-11-09 16:15:14 | 400,000 0 | 400,000 | Form 4 |
| Stuart Bryan See Remarks | 2022-01-21 16:15:24 | 340,000 0 | 340,000 | Form 4 |
| Wallace Owen B. Chief Scientific Officer | 2020-09-14 16:19:08 | 209,030 0 | 209,030 | Form 4 |
| Moxham Christopher Chief Scientific Officer | 2021-08-12 16:20:57 | 176,073 0 | 176,073 | Form 4 |
| Rajavelu Esther Chief Financial Officer | 2023-02-13 16:15:14 | 160,000 0 | 160,000 | Form 4 |
| Oltmans Curtis Gale Chief Legal Officer | 2024-01-30 21:00:05 | 150,000 0 | 150,000 | Form 4 |
| Dunn Judith See Remarks | 2022-01-21 16:15:31 | 140,890 0 | 140,890 | Form 4 |
| Hayes Melvin H. III Chief Operating Officer | 2023-04-28 16:17:16 | 115,000 0 | 115,000 | Form 4 |
| Musso Alan A Chief Financial Officer | 2024-01-30 21:05:10 | 100,000 0 | 100,000 | Form 4 |
| Cadavid Diego SVP Clinical Development | 2020-07-02 16:19:30 | 65,714 0 | 65,714 | Form 4 |
| Morabito Christopher Chief Medical Officer | 2022-01-21 16:15:17 | 59,744 0 | 59,744 | Form 4 |
| Sapir Alex See Remarks | 2024-03-05 16:15:17 | 43,360 0 | 43,360 | Form 4 |
| Thomson Peter G. VP Finance & Accounting | 2022-01-21 16:15:41 | 40,000 0 | 40,000 | Form 4 |
| Gould Robert J Interim President & CEO | 2023-06-29 16:16:13 | 30,000 0 | 30,000 | Form 4 |
| Ezekowitz Alan Director | 2023-06-29 16:16:17 | 30,000 0 | 30,000 | Form 4 |
| Dorton Katina Director | 2023-06-29 16:16:51 | 30,000 0 | 30,000 | Form 4 |
| Banks Sonja Director | 2023-06-29 16:16:51 | 30,000 0 | 30,000 | Form 4 |
| Haviland Kate Director | 2023-06-29 16:16:52 | 30,000 0 | 30,000 | Form 4 |
| GERAGHTY JAMES A Director | 2023-06-29 16:23:17 | 30,000 0 | 30,000 | Form 4 |
| Collins James J. Director | 2023-06-29 16:16:09 | 30,000 0 | 30,000 | Form 4 |
| Tourangeau Greg Vice President, Finance | 2024-03-08 18:05:06 | 11,807 0 | 11,807 | Form 4 |